Correction to: Current Neurolology and Neuroscience Reports (2020) 20: 56

https://doi.org/10.1007/s11910-020-01078-8

The original article contained the following two errors:

  1. 1-

    In reference number 95:

95. •• Sardh E, Rejkjaer L, Andersson DE, Harper P. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007;46:335–49. https://doi.org/10.2165/00003088-200746040-00006This was a phase-1 trial of givosiran in AIP patients. It showed that sustained reductions in ALAS1 mRNA, ALA, and PBG levels occur after monthly subcutaneus injection of the medication and were associated with significant reduction in the annualized attack rate.

Must be corrected to:

95. •• Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. N Engl J Med. 2019;380:549–558. doi: https://doi.org/10.1056/NEJMoa1807838. This was a phase-1 trial of givosiran in AIP patients. It showed that sustained reductions in ALAS1 mRNA, ALA, and PBG levels occur after monthly subcutaneous injection of the medication and were associated with a significant reduction in the annualized attack rate.

  1. 2-

    On page 6 and under Supportive and Symptomatic Treatment:

“Prochlorperazine are ondansetron safe options for nausea and vomiting”.

Must be corrected to:

“Prochlorperazine and ondansetron are safe options for nausea and vomiting”.